更新于：2024-11-01

TTK x CLK2

更新于：2024-11-01

基本信息

关联

项与 TTK x CLK2 相关的药物

CC-671

靶点

CLK2 x TTK

作用机制

CLK2抑制剂 [+1]

在研机构

Celgene Corp.

原研机构

Celgene Corp.

在研适应症

乳腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 TTK x CLK2 相关的临床结果

登录后查看更多信息

100 项与 TTK x CLK2 相关的转化医学

登录后查看更多信息

0 项与 TTK x CLK2 相关的专利（医药）

登录后查看更多信息

项与 TTK x CLK2 相关的文献（医药）

2020-08-01·Cancer Science2区 · 医学

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells

2区 · 医学

ArticleOA

作者: Lei, Zi‐Ning ; Lin, Lizhu ; Zou, Chang ; Wang, Jing‐Quan ; Chen, Zhe‐Sheng ; Teng, Qiu‐Xu ; Wu, Zhuo‐Xun ; Yang, Yuqi ; Wang, Guangsuo ; Sun, Lingling

AbstractOne pivotal factor that leads to multidrug resistance (MDR) is the overexpression of ABCG2. Therefore, tremendous effort has been devoted to the search of effective reversal agents to overcome ABCG2‐mediated MDR. CC‐671 is a potent and selective inhibitor of both TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2). It represents a new class of cancer therapeutic drugs. In this study, we show that CC‐671 is an effective ABCG2 reversal agent that enhances the efficacy of chemotherapeutic drugs in ABCG2‐overexpressing lung cancer cells. Mechanistic studies show that the reversal effect of CC‐671 is primarily attributed to the inhibition of the drug efflux activity of ABCG2, which leads to an increased intracellular level of chemotherapeutic drugs. In addition, CC‐671 does not alter the protein expression or subcellular localization of ABCG2. The computational molecule docking analysis suggests CC‐671 has high binding affinity to the drug‐binding site of ABCG2. In conclusion, we reveal the interaction between CC‐671 and ABCG2, providing a rationale for the potential combined use of CC‐671 with ABCG2 substrate to overcome MDR.

2019-08-01·European Journal of Medicinal Chemistry1区 · 医学

Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective

1区 · 医学

Review

作者: Yang, Xiaohong ; Wang, Shutao ; Li, Chenchen ; Liu, Junli ; Jiang, Mengnan ; Liang, Di ; Sun, Wei ; Zhou, Xiaoping ; Zhang, Muxin ; Li, Jiaguo ; Zhang, Chaozai

As a dual-specificity protein kinase, monopolar spindle 1 (Mps1) is one of the main kinases involved in kinetochore localization and the spindle assembly checkpoint (SAC). Cancer cells often display chromosomal instability, which is a consequence of disfunction of cell cycle checkpoints partially. Mps1 is overexpressed in multiple cancer types to face the pressure from aberrant chromosomes and centrosomes. Therefore, Mps1 is a potential targeting approach to cancer treatment. Several compounds targeting Mps1 have been developed and approved to begin clinical trials for advanced nonhaematologic malignancies treatments, including but not limited to triple negative breast cancer (TNBC) treatment. In this review, we will highlight typical Mps1 inhibitors developed during the last decade and provide a reference for more potential Mps1 inhibitors exploration in the future.

2018-08-01·Molecular Cancer Therapeutics2区 · 医学

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

2区 · 医学

Article

作者: Shi, Tao ; Tran, Tam ; Boylan, John F. ; Deyanat-Yazdi, Gordafaried ; Ning, Yuhong ; Zhu, Dan ; Barnes, Leo A. ; Peng, Sophie X. ; Mikolon, David ; Xu, Shuichan ; Narla, Rama Krishna ; Raymon, Heather K. ; Jiang, Ning ; Riggs, Jennifer R.

AbstractHistorically, phenotypic-based drug discovery has yielded a high percentage of novel drugs while uncovering new tumor biology. CC-671 was discovered using a phenotypic screen for compounds that preferentially induced apoptosis in triple-negative breast cancer cell lines while sparing luminal breast cancer cell lines. Detailed in vitro kinase profiling shows CC-671 potently and selectively inhibits two kinases—TTK and CLK2. Cellular mechanism of action studies demonstrate that CC-671 potently inhibits the phosphorylation of KNL1 and SRp75, direct TTK and CLK2 substrates, respectively. Furthermore, CC-671 causes mitotic acceleration and modification of pre-mRNA splicing leading to apoptosis, consistent with cellular TTK and CLK inhibition. Correlative analysis of genomic and potency data against a large panel of breast cancer cell lines identifies breast cancer cells with a dysfunctional G1–S checkpoint as more sensitive to CC-671, suggesting synthetic lethality between G1–S checkpoint and TTK/CLK2 inhibition. Furthermore, significant in vivo CC-671 efficacy was demonstrated in two cell line–derived and one patient tumor-derived xenograft models of triple-negative breast cancer (TNBC) following weekly dosing. These findings are the first to demonstrate the unique inhibitory combination activity of a dual TTK/CLK2 inhibitor that preferably kills TNBC cells and shows synthetic lethality with a compromised G1–S checkpoint in breast cancer cell lines. On the basis of these data, CC-671 was moved forward for clinical development as a potent and selective TTK/CLK2 inhibitor in a subset of patients with TNBC. Mol Cancer Ther; 17(8); 1727–38. ©2018 AACR.